# Liquid Biopsy Evaluation and Repository Development at Princess Margaret

> **NCT03702309** · — · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 2500 (estimated)

## Conditions studied

- Cancer
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Ovarian Cancer
- Melanoma
- Lymphoma
- Leukemia
- Mutation
- Lynch Syndrome
- Cowden Syndrome
- BRCA1 Mutation
- BRCA2 Mutation
- Uterine Cancer
- Myeloma
- Kidney Cancer
- Head and Neck Cancer
- Meningioma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03702309
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2017-08-03
- **Primary completion:** 2026-07-06
- **Final completion:** 2026-07-06
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03702309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03702309, "Liquid Biopsy Evaluation and Repository Development at Princess Margaret". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03702309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*